Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Economic returns to medical research funding.

Grant J, Buxton MJ.

BMJ Open. 2018 Sep 10;8(9):e022131. doi: 10.1136/bmjopen-2018-022131.

2.

Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes.

Glover M, Montague E, Pollitt A, Guthrie S, Hanney S, Buxton M, Grant J.

Health Res Policy Syst. 2018 Jan 10;16(1):1. doi: 10.1186/s12961-017-0276-7.

3.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

4.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

5.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

6.

Labor Dystocia: A Common Approach to Diagnosis.

Neal JL, Lowe NK, Schorn MN, Holley SL, Ryan SL, Buxton M, Wilson-Liverman AM.

J Midwifery Womens Health. 2015 Sep-Oct;60(5):499-509. doi: 10.1111/jmwh.12360. Review.

PMID:
26461189
7.

Labor Dystocia: Uses of Related Nomenclature.

Neal JL, Ryan SL, Lowe NK, Schorn MN, Buxton M, Holley SL, Wilson-Liverman AM.

J Midwifery Womens Health. 2015 Sep-Oct;60(5):485-98. doi: 10.1111/jmwh.12355. Review.

PMID:
26461188
8.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

9.

Interprofessional simulation of a retained placenta and postpartum hemorrhage.

Phillippi JC, Buxton M, Overstreet M.

Nurse Educ Pract. 2015 Jul;15(4):333-8. doi: 10.1016/j.nepr.2015.02.001. Epub 2015 Feb 14.

PMID:
25707310
10.

Reforming the cancer drug fund.

Buxton M, Longworth L, Raftery J, Sculpher M, Towse A.

BMJ. 2014 Nov 28;349:g7276. doi: 10.1136/bmj.g7276. No abstract available.

PMID:
25432928
11.

Simulation: a new approach to teaching ethics.

Buxton M, Phillippi JC, Collins MR.

J Midwifery Womens Health. 2015 Jan-Feb;60(1):70-4. doi: 10.1111/jmwh.12185. Epub 2014 Aug 20.

PMID:
25141791
12.

Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes.

Glover M, Buxton M, Guthrie S, Hanney S, Pollitt A, Grant J.

BMC Med. 2014 Jun 16;12:99. doi: 10.1186/1741-7015-12-99.

13.

Twitter™ as a study prompt: engaging adult learners on the go.

Phillippi JC, Buxton M.

J Nurs Educ. 2014 Jun;53(6):363. doi: 10.3928/01484834-20140521-11. No abstract available.

PMID:
24893342
14.

Personal and Professional Knowledge of and Experience With Suicide and Suicide Prevention Among Stakeholders in Clinical and Community Practice.

Matthieu MM PhD, Gardiner G, Ziegemeier E, Buxton M, Han L, Cross W.

Soc Work Ment Health. 2014 May 30;12(5-6):443-456. doi: 10.1080/15332985.2014.884517. eCollection 2014.

15.

Cost-effectiveness of the National Health Service Abdominal Aortic Aneurysm Screening Programme in England.

Glover MJ, Kim LG, Sweeting MJ, Thompson SG, Buxton MJ.

Br J Surg. 2014 Jul;101(8):976-82. doi: 10.1002/bjs.9528. Epub 2014 May 27.

16.

Understanding factors associated with the translation of cardiovascular research: a multinational case study approach.

Wooding S, Hanney SR, Pollitt A, Grant J, Buxton MJ; Project Retrosight Team.

Implement Sci. 2014 Apr 21;9(1):47. doi: 10.1186/1748-5908-9-47.

17.

Using a service sector segmented approach to identify community stakeholders who can improve access to suicide prevention services for veterans.

Matthieu MM, Gardiner G, Ziegemeier E, Buxton M.

Mil Med. 2014 Apr;179(4):388-95. doi: 10.7205/MILMED-D-13-00306.

PMID:
24690963
18.

Strategies to reduce the harmful effects of extreme heat events: a four-city study.

White-Newsome JL, McCormick S, Sampson N, Buxton MA, O'Neill MS, Gronlund CJ, Catalano L, Conlon KC, Parker EA.

Int J Environ Res Public Health. 2014 Feb 13;11(2):1960-88. doi: 10.3390/ijerph110201960.

20.

Air pollution, inflammation and preterm birth: a potential mechanistic link.

Vadillo-Ortega F, Osornio-Vargas A, Buxton MA, Sánchez BN, Rojas-Bracho L, Viveros-Alcaráz M, Castillo-Castrejón M, Beltrán-Montoya J, Brown DG, O'Neill MS.

Med Hypotheses. 2014 Feb;82(2):219-24. doi: 10.1016/j.mehy.2013.11.042. Epub 2013 Dec 11.

21.

Children must be protected from the tobacco industry's marketing tactics.

Hopkinson N, Wallis C, Higgins B, Gaduzo S, Sherrington R, Keilty S, Stern M, Britton J, Bush A, Moxham J, Sylvester K, Griffiths V, Sutherland T, Crossingham I, Raju R, Spencer C, Safavi S, Deegan P, Seymour J, Hickman K, Hughes J, Wieboldt J, Shaheen F, Peedell C, Mackenzie N, Nicholl D, Jolley C, Crooks G, Crooks G, Dow C, Deveson P, Bintcliffe O, Gray B, Kumar S, Haney S, Docherty M, Thomas A, Chua F, Dwarakanath A, Summers G, Prowse K, Lytton S, Ong YE, Graves J, Banerjee T, English P, Leonard A, Brunet M, Chaudhry N, Ketchell RI, Cummings N, Lebus J, Sharp C, Meadows C, Harle A, Stewart T, Parry D, Templeton-Wright S, Moore-Gillon J, Stratford- Martin J, Saini S, Matusiewicz S, Merritt S, Dowson L, Satkunam K, Hodgson L, Suh ES, Durrington H, Browne E, Walters N, Steier J, Barry S, Griffiths M, Hart N, Nikolic M, Berry M, Thomas A, Miller J, McNicholl D, Marsden P, Warwick G, Barr L, Adeboyeku D, Mohd Noh MS, Griffiths P, Davies L, Quint J, Lyall R, Shribman J, Collins A, Goldman J, Bloch S, Gill A, Man W, Christopher A, Yasso R, Rajhan A, Shrikrishna D, Moore C, Absalom G, Booton R, Fowler RW, Mackinlay C, Sapey E, Lock S, Walker P, Jha A, Satia I, Bradley B, Mustfa N, Haqqee R, Thomas M, Patel A, Redington A, Pillai A, Keaney N, Fowler S, Lowe L, Brennan A, Morrison D, Murray C, Hankinson J, Dutta P, Maddocks M, Pengo M, Curtis K, Rafferty G, Hutchinson J, Whitfield R, Turner S, Breen R, Naveed SU, Goode C, Esterbrook G, Ahmed L, Walker W, Ford D, Connett G, Davidson P, Elston W, Stanton A, Morgan D, Myerson J, Maxwell D, Harrris A, Parmar S, Houghton C, Winter R, Puthucheary Z, Thomson F, Sturney S, Harvey J, Haslam PL, Patel I, Jennings D, Range S, Mallia-Milanes B, Collett A, Tate P, Russell R, Feary J, O'Driscoll R, Eaden J, Round J, Sharkey E, Montgomery M, Vaughan S, Scheele K, Lithgow A, Partridge S, Chavasse R, Restrick L, Agrawal S, Abdallah S, Lacy-Colson A, Adams N, Mitchell S, Haja Mydin H, Ward A, Denniston S, Steel M, Ghosh D, Connellan S, Rigge L, Williams R, Grove A, Anwar S, Dobson L, Hosker H, Stableforth D, Greening N, Howell T, Casswell G, Davies S, Tunnicliffe G, Mitchelmore P, Phitidis E, Robinson L, Prowse K, Bafadhel M, Robinson G, Boland A, Lipman M, Bourke S, Kaul S, Cowie C, Forrest I, Starren E, Burke H, Furness J, Bhowmik A, Everett C, Seaton D, Holmes S, Doe S, Parker S, Graham A, Paterson I, Maqsood U, Ohri C, Iles P, Kemp S, Iftikhar A, Carlin C, Fletcher T, Emerson P, Beasley V, Ramsay M, Buttery R, Mungall S, Crooks S, Ridyard J, Ross D, Guadagno A, Holden E, Coutts I, Cullen K, O'Connor S, Barker J, Sloper K, Watson J, Smith P, Anderson P, Brown L, Nyman C, Milburn H, Clive A, Serlin M, Bolton C, Fuld J, Powell H, Dayer M, Woolhouse I, Georgiadi A, Leonard H, Dodd J, Campbell I, Ruiz G, Zurek A, Paton JY, Malin A, Wood F, Hynes G, Connell D, Spencer D, Brown S, Smith D, Cooper D, O'Kane C, Hicks A, Creagh-Brown B, Lordan J, Nickol A, Primhak R, Fleming L, Powrie D, Brown J, Zoumot Z, Elkin S, Szram J, Scaffardi A, Marshall R, Macdonald I, Lightbody D, Farmer R, Wheatley I, Radnan P, Lane I, Booth A, Tilbrook S, Capstick T, Hewitt L, McHugh M, Nelson C, Wilson P, Padmanaban V, White J, Davison J, O'Callaghan U, Hodson M, Edwards J, Campbell C, Ward S, Wooler E, Ringrose E, Bridges D, Matthew Hodson, John Edwards, Colin Campbell, Simon Ward, Edwina Wooler, Elizabeth Ringrose, Diana Bridges, Rosalind Backham, Kim Randall, Tracey Mathieson, Long A, Parkes M, Clarke S, Allen B, Connelly C, Forster G, Hoadley J, Martin K, Barnham K, Khan K, Munday M, Edwards C, O'Hara D, Turner S, Pieri-Davies S, Ford K, Daniels T, Wright J, Towns R, Fern K, Butcher J, Burgin K, Winter B, Freeman D, Olive S, Gray L, Pye K, Roots D, Cox N, Davies CA, Wicker J, Hilton K, Lloyd J, MacBean V, Wood M, Kowal J, Downs J, Ryan H, Guyatt F, Nicoll D, Lyons E, Narasimhan D, Rodman A, Walmsley S, Newey A, Buxton M, Dewar M, Cooper A, Reilly J, Lloyd J, Macmillan AB, Roots D, Olley A, Voase N, Martin S, McCarvill I, Christensen A, Agate R, Heslop K, Timlett A, Hailes K, Davey C, Pawulska B, Lane A, Ioakim S, Hough A, Treharne J, Jones H, Winter-Burke A, Miller L, Connolly B, Bingham L, Fraser U, Bott J, Johnston C, Graham A, Curry D, Sumner H, Costello CA, Bartoszewicz C, Badman R, Williamson K, Taylor A, Purcell H, Barnett E, Molloy A, Crawfurd L, Collins N, Monaghan V, Mir M, Lord V, Stocks J, Edwards A, Greenhalgh T, Lenney W, McKee M, McAuley D, Majeed A, Cookson J, Baker E, Janes S, Wedzicha W, Lomas Dean D, Harrison B, Davison T, Calverley P, Wilson R, Stockley R, Ayres J, Gibson J, Simpson J, Burge S, Warner J, Lenney W, Thomson N, Davies P, Woodcock A, Woodhead M, Spiro S, Ormerod L, Bothamley G, Partridge M, Shields M, Montgomery H, Simonds A, Barnes P, Durham S, Malone S, Arabnia G, Olivier S, Gardiner K, Edwards S.

BMJ. 2013 Dec 9;347:f7358. doi: 10.1136/bmj.f7358. No abstract available.

22.

Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness.

Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, Buxton MJ, Powell JT.

Health Technol Assess. 2013 Sep;17(41):1-118. doi: 10.3310/hta17410. Review.

23.

Exploring what lies behind public preferences for avoiding health losses caused by lapses in healthcare safety and patient lifestyle choices.

Singh J, Longworth L, Baine A, Lord J, Orr S, Buxton M.

BMC Health Serv Res. 2013 Jul 2;13:249. doi: 10.1186/1472-6963-13-249.

24.

Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures.

Chambers JD, Lord J, Cohen JT, Neumann PJ, Buxton MJ.

Value Health. 2013 Jun;16(4):629-38. doi: 10.1016/j.jval.2013.02.011. Epub 2013 May 10.

25.

Staying cool in a changing climate: Reaching vulnerable populations during heat events.

Sampson NR, Gronlund CJ, Buxton MA, Catalano L, White-Newsome JL, Conlon KC, O'Neill MS, McCormick S, Parker EA.

Glob Environ Change. 2013 Apr;23(2):475-484. doi: 10.1016/j.gloenvcha.2012.12.011.

26.

Developing safety criteria for introducing new agents into neoadjuvant trials.

DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L.

Clin Cancer Res. 2013 Jun 1;19(11):2817-23. doi: 10.1158/1078-0432.CCR-12-2620. Epub 2013 Mar 7. Review.

27.

Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women.

Foxman B, Buxton M.

Curr Infect Dis Rep. 2013 Apr;15(2):124-9. doi: 10.1007/s11908-013-0317-5.

28.

Air pollution, inflammation and preterm birth in Mexico City: study design and methods.

O'Neill MS, Osornio-Vargas A, Buxton MA, Sánchez BN, Rojas-Bracho L, Castillo-Castrejon M, Mordhukovich IB, Brown DG, Vadillo-Ortega F.

Sci Total Environ. 2013 Mar 15;448:79-83. doi: 10.1016/j.scitotenv.2012.10.079. Epub 2012 Nov 21.

29.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L.

J Clin Oncol. 2012 Dec 20;30(36):4584-6; author reply 4588-9. doi: 10.1200/JCO.2012.44.1022. Epub 2012 Nov 19. No abstract available.

PMID:
23169510
30.

Physical activity in England: who is meeting the recommended level of participation through sports and exercise?

Anokye NK, Pokhrel S, Buxton M, Fox-Rushby J.

Eur J Public Health. 2013 Jun;23(3):458-64. doi: 10.1093/eurpub/cks127. Epub 2012 Oct 4.

31.

Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach.

Mistry H, Morris S, Dyer M, Kotseva K, Wood D, Buxton M; EUROACTION study group.

BMJ Open. 2012 Oct 11;2(5). pii: e001029. doi: 10.1136/bmjopen-2012-001029. Print 2012.

32.

Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening.

Thompson SG, Ashton HA, Gao L, Buxton MJ, Scott RA; Multicentre Aneurysm Screening Study (MASS) Group.

Br J Surg. 2012 Dec;99(12):1649-56. doi: 10.1002/bjs.8897. Epub 2012 Oct 3.

33.

Does responsibility affect the public's valuation of health care interventions? A relative valuation approach to health care safety.

Singh J, Lord J, Longworth L, Orr S, McGarry T, Sheldon R, Buxton M.

Value Health. 2012 Jul-Aug;15(5):690-8. doi: 10.1016/j.jval.2012.02.005. Epub 2012 Apr 11.

34.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

35.

Bayesian meta-analysis on medical devices: application to implantable cardioverter defibrillators.

Youn JH, Lord J, Hemming K, Girling A, Buxton M.

Int J Technol Assess Health Care. 2012 Apr;28(2):115-24. doi: 10.1017/S0266462312000037.

36.

Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial.

Sharples LD, Jackson C, Wheaton E, Griffith G, Annema JT, Dooms C, Tournoy KG, Deschepper E, Hughes V, Magee L, Buxton M, Rintoul RC.

Health Technol Assess. 2012;16(18):1-75, iii-iv. doi: 10.3310/hta16180.

37.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

38.

Factors predicting Medicare national coverage: an empirical analysis.

Chambers JD, Morris S, Neumann PJ, Buxton MJ.

Med Care. 2012 Mar;50(3):249-56. doi: 10.1097/MLR.0b013e318241eb40.

PMID:
22193418
39.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28.

40.

What values do the public want their health care systems to use in evaluating technologies?

Buxton MJ, Chambers JD.

Eur J Health Econ. 2011 Aug;12(4):285-8. doi: 10.1007/s10198-011-0320-4. No abstract available.

41.

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF.

JAMA. 2011 May 11;305(18):1873-81. doi: 10.1001/jama.2011.593.

42.

Project Retrosight: Understanding the Returns from Cardiovascular and Stroke Research: The Policy Report.

Wooding S, Hanney S, Pollitt A, Buxton M, Grant J.

Rand Health Q. 2011 Mar 1;1(1):16. eCollection 2011 Spring.

43.

The demand for sports and exercise: results from an illustrative survey.

Anokye NK, Pokhrel S, Buxton M, Fox-Rushby J.

Eur J Health Econ. 2012 Jun;13(3):277-87. doi: 10.1007/s10198-011-0304-4. Epub 2011 Feb 23.

44.

Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial.

Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B.

Clin Infect Dis. 2011 Jan 1;52(1):23-30. doi: 10.1093/cid/ciq073.

45.

A public health academic-practice partnership to develop capacity for exercise evaluation and improvement planning.

Wright KS, Thomas MW, Durham DP Jr, Jackson LM, Porth LL, Buxton M.

Public Health Rep. 2010 Nov-Dec;125 Suppl 5:107-16.

46.

Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus.

Vallejo-Torres L, Steuten L, Parkinson B, Girling AJ, Buxton MJ.

Med Decis Making. 2011 Jul-Aug;31(4):596-610. doi: 10.1177/0272989X10388041. Epub 2010 Dec 2.

PMID:
21127320
47.

The future of clinical trials in secondary prevention after acute coronary syndromes.

Bueno H, Armstrong PW, Buxton MJ, Danchin N, Lubsen J, Roland E, Verheugt FW, Zalewski A, Jackson N, Komajda M, Steg PG; Cardiovascular Round Table Clinical Trials ThinkTank participants.

Eur Heart J. 2011 Jul;32(13):1583-9. doi: 10.1093/eurheartj/ehq388. Epub 2010 Oct 29. No abstract available.

PMID:
21037255
48.

Assessment of potential measures in models of progression in Alzheimer disease.

McLaughlin T, Buxton M, Mittendorf T, Redekop W, Mucha L, Darba J, Jonsson L, Lacey L, Leibman C.

Neurology. 2010 Oct 5;75(14):1256-62. doi: 10.1212/WNL.0b013e3181f6133d.

PMID:
20921511
49.

Web 2.0: easy tools for busy clinicians.

Phillippi JC, Buxton M.

J Midwifery Womens Health. 2010 Sep-Oct;55(5):472-6. doi: 10.1016/j.jmwh.2010.05.009.

PMID:
20732669
50.

Economic evaluation of healthcare safety: which attributes of safety do healthcare professionals consider most important in resource allocation decisions?

Steuten L, Buxton M.

Qual Saf Health Care. 2010 Oct;19(5):e6. doi: 10.1136/qshc.2008.027870. Epub 2010 Aug 10.

PMID:
20702440

Supplemental Content

Loading ...
Support Center